Skip to content

Compounds · Brain & nerves · Growth hormone stimulation and release

CJC-1295 (with and without DAC)

On NovaEvumFull protocol

Modified GRF (1-29), Mod GRF 1-29, CJC-1295 without DAC, CJC-1295 DAC, tetrasubstituted GRF (1-29)

Long-acting synthetic analog of growth hormone-releasing hormone, shown in early studies to raise GH and IGF-1 levels. Not FDA-approved for any use, with no major 2020–2025 trials; banned by WADA and sold as a research chemical, though a 2024 FDA status review opened it to further compounding evaluation without approving it.

0.1–0.3 mg of each nightly (blend)

Research score 40/100. Reference only, not a prescription.

  • Growth Hormone Release
  • Muscle Growth
  • Fat Loss
  • Recovery Enhancement
  • Sleep Improvement
US status
Research Chemical
Approval
Not FDA Approved; Prohibited by WADA. Re-evaluated by FDA in 2024 for potential compounding.
Evidence
No active or recent clinical trials. Early-phase studies were conducted prior to 2020 but did not lead to clinical approval.
Research score
40 / 100
Indication
Research Only - No Medical Indication
Origin
Canada
Source category
Brain & Nervous System
Status group
Research chemical

Mechanism

Binds GHRH receptors on the pituitary to trigger GH release via cAMP signaling. The DAC version attaches to serum albumin, extending its half-life from about 30 minutes to 6–8 days for sustained GH/IGF-1 elevation; the non-DAC form (Mod GRF 1-29) acts more briefly.

Safety file

Long-term human safety is unknown. The FDA has flagged cardiac event risk, plus concerns tied to elevated GH/IGF-1, including insulin resistance.

  • Injection site reactions
  • Temporary numbness in extremities
  • Water retention
  • Headache
  • Joint stiffness
  • Increased insulin resistance

Reconstitution

Concentration by vial size and water volume
Vial2 mL water3 mL water
10 mg5 mg/mL3.33 mg/mL

The classic GH pairing of CJC-1295 (No DAC) and Ipamorelin in a 1:1 ratio. The 10 mg vial holds 5 mg of each. Doses below are stated per peptide (they always move together); the calculator works in total blend mg, so 0.2 mg of each peptide is 0.4 mg of total blend.

  1. Use bacteriostatic water as the diluent.
  2. Add the water slowly, letting it run down the inside wall of the vial rather than onto the powder.
  3. Swirl gently to mix, then leave it to dissolve. Do not shake.
  4. Give it a few minutes. The finished solution should be clear and colourless.

Full mixing method

Protocol

Route: Subcutaneous

Why these two together

  • CJC-1295 (No DAC) tells the pituitary to make growth hormone, while Ipamorelin tells it to release it: two different signals on the same gland
  • The No DAC version is used because its short half-life lines up with Ipamorelin, which keeps the natural pulsing pattern intact
  • They are combined in one syringe and one shot

Standard protocol (subcutaneous)

  • 0.1 mg of each peptide before bed is the standard starting dose, moving to 0.2 mg of each for most people
  • On the 10 mg vial (5 mg of each) at a 2 mL fill, 0.1 mg of each is a 0.04 mL draw (4 units) and 0.2 mg of each is 0.08 mL (8 units)
  • Dose once daily, 5 days on, 2 days off

Timing matters

  • Inject before bed, at least 2 hours after your last meal
  • Food (especially carbs and fat) blunts the GH pulse, and the body releases its own GH overnight, so a fasted bedtime shot lines up with natural timing
  • A fasted morning or post-workout dose is the other common slot

Titration and ceiling

  • Start at 0.1 mg of each and increase by about 0.05 mg every 1 to 2 weeks if you want, up to a common ceiling of 0.3 mg of each per day (0.12 mL / 12 units at the 2 mL fill)
  • 0.1 mg is already a saturating dose for many, so more is not always better

Dosing detail

  • 0.1 mg of each peptide is the standard start, 0.2 mg of each suits most people, 0.3 mg of each is a common ceiling.
  • At the 2 mL fill: 0.1 mg of each is 0.04 mL (4 units), 0.2 mg is 0.08 mL (8 units), 0.3 mg is 0.12 mL (12 units).
  • Inject once daily before bed, fasted (2 hours after eating), 5 days on and 2 off.
  • Both peptides are short-acting and share one syringe, so the pairing keeps the natural pulsatile GH release.

Duration

  • Run 8 to 12 weeks (extend to 16 if desired), 5 on / 2 off, then a break.

Notes

  • The most common GH peptide pairing.
  • One daily shot covers both peptides instead of running two separate vials.
  • A brief flush after injecting is common and harmless. Inject subcutaneously and rotate sites.

Storage and handling

  • Keep the powdered (lyophilized) vial in a cool, dark place. Refrigerate it for longer-term storage before mixing.
  • Once reconstituted and refrigerated at 2–8 °C away from light, use the vial within 28 days.
  • Do not freeze a reconstituted vial, and keep it away from heat and sunlight.
  • If the solution turns cloudy, develops floating particles, or shows any other sign of degradation, stop using that vial.

Storage rules and when to discard

NovaEvum vial

Worksheet

2 mL bacteriostatic water yields 2.5 mg/mL of each peptide. A 100 mcg-of-each pulse is 4 units; 200 mcg of each is 8 units.

Catalog fill
5 mg + 5 mg
Typical water
2 mL
Route
Subcutaneous
Cycle
8–12 weeks.
StepAmountFrequencyNotes
Standard pulse100 mcg each1–2× daily4 units from a 2 mL reconstitution
Higher pulse200 mcg each1–2× daily8 units
  • You cannot change the CJC:Ipamorelin ratio from this vial.
  • Do not also run a separate Ipamorelin vial on the same days unless you intend to raise only the secretagogue.
  • Bacteriostatic water: 20–25 °C. Do not refrigerate the diluent.
  • Amounts on this sheet are reconstitution math for the vial, not a recommendation.